The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects
Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage w...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-07, Vol.17 (7), p.e0270911-e0270911 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0270911 |
|---|---|
| container_issue | 7 |
| container_start_page | e0270911 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Cairoli, Victoria De Matteo, Elena Casciato, Paola Ameigeiras, Beatriz Preciado, María Victoria Valva, Pamela |
| description | Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage was evaluated in plasma samples at time of biopsy in 120 patients with different hepatic conditions (56 HCV, 20 HCV/HIV, 10 HBV and 34 MAFLD). sCD163 values were compared with those of healthy donors and analyzed related to histological damage. sCD163 together with other clinical parameters were used to create a logistical regression model to predict significant fibrosis. Only patients with viral hepatitis showed higher sCD163 values compared to the control group (HCV p |
| doi_str_mv | 10.1371/journal.pone.0270911 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2686270154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A709492350</galeid><doaj_id>oai_doaj_org_article_98dfe1108a5e447d99b13748fdc3932e</doaj_id><sourcerecordid>A709492350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5141-ec4fc14bc40b372143ee883d9d232cfed05e7621415a44e601a72a7f6d7bb2bb3</originalsourceid><addsrcrecordid>eNqNk1uLEzEUxwdR3It-A8GAIOtDu8kkc3sRlnppYWFB176GTHKmTc0k3WSmuA9-dzN2lB3ZB8lDwskv_5NzS5JXBM8JLcjlzvXeCjPfOwtznBa4IuRJckoqms7yFNOnD84nyVkIO4wzWub58-SEZkVV0LI8TX7ebgHtwTfOt8JKQK5BwZm-NoAWH0hOkQhIIOvsTNuDCPoAqNauFf47-AE20eKREq3YANIWya13VkthzD1aLtZIWDXsl8vVOl43IDtQKPT1Lp7Ci-RZI0yAl-N-nnz79PF2sZxd33xeLa6uZzIjjMxAskYSVkuGa1qkhFGAsqSqUilNZQMKZ1Dk0U4ywRjkmIgiFUWTq6Ku07qm58nro-7euMDHzAWe5mUeE0cyFonVkVBO7Pje6xjhPXdC898G5zdc-E5LA7wqVQOE4FJkwFihqqqOBWFloySNCYeo9X701tctKAm288JMRKc3Vm_5xh14lcYgyuEzF6OAd3c9hI63OkgwRlhw_fHfOCtiYSP65h_08ehGaiNiALEMLvqVgyi_io3DqpRmOFLzR6i4FLRaxjZrdLRPHrybPIhMBz-6jehD4KuvX_6fvVlP2bcP2C0I022Hpuy0s2EKsiMovQvBQ_M3yQTzYUr-ZIMPU8LHKaG_ALDgAV4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2686270154</pqid></control><display><type>article</type><title>The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects</title><source>Open Access: PubMed Central</source><source>PLoS</source><source>DOAJ Directory of Open Access Journals</source><source>Free Full-Text Journals in Chemistry</source><source>EZB Electronic Journals Library</source><creator>Cairoli, Victoria ; De Matteo, Elena ; Casciato, Paola ; Ameigeiras, Beatriz ; Preciado, María Victoria ; Valva, Pamela</creator><contributor>Sitia, Giovanni</contributor><creatorcontrib>Cairoli, Victoria ; De Matteo, Elena ; Casciato, Paola ; Ameigeiras, Beatriz ; Preciado, María Victoria ; Valva, Pamela ; Sitia, Giovanni</creatorcontrib><description>Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage was evaluated in plasma samples at time of biopsy in 120 patients with different hepatic conditions (56 HCV, 20 HCV/HIV, 10 HBV and 34 MAFLD). sCD163 values were compared with those of healthy donors and analyzed related to histological damage. sCD163 together with other clinical parameters were used to create a logistical regression model to predict significant fibrosis. Only patients with viral hepatitis showed higher sCD163 values compared to the control group (HCV p<0.0001; HCV/HIV p<0.0001; HBV p = 0.0003), but no significant differences regarding fibrosis stages were observed. The proposed model predicts fibrosis severity using the logarithm sCD163 concentration, platelet count and age, it demonstrated to be a good marker for the HCV monoinfected group (AUROC 0.834) and an excellent one for the HCV/HIV co-infected group (AUROC 0.997). Moreover, the model displayed a diagnostic performance similar to FIB-4 in HCV cases and FIB-4 and APRI in HCV/HIV coinfected cases, and it even managed to correctly classify some cases that had been misclassified. The proposed model is able to determine, in a non-invasive way, the liver fibrosis stage of HCV and HCV/HIV patients, so after validation, it could be used in a complementary way in the clinical practice whenever APRI and FIB-4 failed to determine damage severity in HCV and HCV/HIV cases.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0270911</identifier><identifier>PMID: 35797388</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Analysis ; Biological markers ; Biology and Life Sciences ; Biomarkers ; Biopsy ; CD163 antigen ; Cell activation ; Damage assessment ; Diagnosis ; Disease prevention ; Fibrosis ; Genetic aspects ; Health aspects ; Hepatitis ; Hepatitis B ; Hepatitis C ; HIV ; HIV patients ; Hospitals ; Human immunodeficiency virus ; Infections ; Inflammation ; Liver ; Liver diseases ; Macrophages ; Medicine and health sciences ; Metabolism ; Modelling ; Obesity ; Patients ; Plasma ; Proteins ; Regression models ; Serology ; Variables</subject><ispartof>PloS one, 2022-07, Vol.17 (7), p.e0270911-e0270911</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Cairoli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Cairoli et al 2022 Cairoli et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5141-ec4fc14bc40b372143ee883d9d232cfed05e7621415a44e601a72a7f6d7bb2bb3</citedby><cites>FETCH-LOGICAL-c5141-ec4fc14bc40b372143ee883d9d232cfed05e7621415a44e601a72a7f6d7bb2bb3</cites><orcidid>0000-0003-3994-2401</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262184/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262184/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,2914,23846,27903,27904,53769,53771,79346,79347</link.rule.ids></links><search><contributor>Sitia, Giovanni</contributor><creatorcontrib>Cairoli, Victoria</creatorcontrib><creatorcontrib>De Matteo, Elena</creatorcontrib><creatorcontrib>Casciato, Paola</creatorcontrib><creatorcontrib>Ameigeiras, Beatriz</creatorcontrib><creatorcontrib>Preciado, María Victoria</creatorcontrib><creatorcontrib>Valva, Pamela</creatorcontrib><title>The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects</title><title>PloS one</title><description>Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage was evaluated in plasma samples at time of biopsy in 120 patients with different hepatic conditions (56 HCV, 20 HCV/HIV, 10 HBV and 34 MAFLD). sCD163 values were compared with those of healthy donors and analyzed related to histological damage. sCD163 together with other clinical parameters were used to create a logistical regression model to predict significant fibrosis. Only patients with viral hepatitis showed higher sCD163 values compared to the control group (HCV p<0.0001; HCV/HIV p<0.0001; HBV p = 0.0003), but no significant differences regarding fibrosis stages were observed. The proposed model predicts fibrosis severity using the logarithm sCD163 concentration, platelet count and age, it demonstrated to be a good marker for the HCV monoinfected group (AUROC 0.834) and an excellent one for the HCV/HIV co-infected group (AUROC 0.997). Moreover, the model displayed a diagnostic performance similar to FIB-4 in HCV cases and FIB-4 and APRI in HCV/HIV coinfected cases, and it even managed to correctly classify some cases that had been misclassified. The proposed model is able to determine, in a non-invasive way, the liver fibrosis stage of HCV and HCV/HIV patients, so after validation, it could be used in a complementary way in the clinical practice whenever APRI and FIB-4 failed to determine damage severity in HCV and HCV/HIV cases.</description><subject>Analysis</subject><subject>Biological markers</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>CD163 antigen</subject><subject>Cell activation</subject><subject>Damage assessment</subject><subject>Diagnosis</subject><subject>Disease prevention</subject><subject>Fibrosis</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>HIV</subject><subject>HIV patients</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Macrophages</subject><subject>Medicine and health sciences</subject><subject>Metabolism</subject><subject>Modelling</subject><subject>Obesity</subject><subject>Patients</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Regression models</subject><subject>Serology</subject><subject>Variables</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1uLEzEUxwdR3It-A8GAIOtDu8kkc3sRlnppYWFB176GTHKmTc0k3WSmuA9-dzN2lB3ZB8lDwskv_5NzS5JXBM8JLcjlzvXeCjPfOwtznBa4IuRJckoqms7yFNOnD84nyVkIO4wzWub58-SEZkVV0LI8TX7ebgHtwTfOt8JKQK5BwZm-NoAWH0hOkQhIIOvsTNuDCPoAqNauFf47-AE20eKREq3YANIWya13VkthzD1aLtZIWDXsl8vVOl43IDtQKPT1Lp7Ci-RZI0yAl-N-nnz79PF2sZxd33xeLa6uZzIjjMxAskYSVkuGa1qkhFGAsqSqUilNZQMKZ1Dk0U4ywRjkmIgiFUWTq6Ku07qm58nro-7euMDHzAWe5mUeE0cyFonVkVBO7Pje6xjhPXdC898G5zdc-E5LA7wqVQOE4FJkwFihqqqOBWFloySNCYeo9X701tctKAm288JMRKc3Vm_5xh14lcYgyuEzF6OAd3c9hI63OkgwRlhw_fHfOCtiYSP65h_08ehGaiNiALEMLvqVgyi_io3DqpRmOFLzR6i4FLRaxjZrdLRPHrybPIhMBz-6jehD4KuvX_6fvVlP2bcP2C0I022Hpuy0s2EKsiMovQvBQ_M3yQTzYUr-ZIMPU8LHKaG_ALDgAV4</recordid><startdate>20220707</startdate><enddate>20220707</enddate><creator>Cairoli, Victoria</creator><creator>De Matteo, Elena</creator><creator>Casciato, Paola</creator><creator>Ameigeiras, Beatriz</creator><creator>Preciado, María Victoria</creator><creator>Valva, Pamela</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3994-2401</orcidid></search><sort><creationdate>20220707</creationdate><title>The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects</title><author>Cairoli, Victoria ; De Matteo, Elena ; Casciato, Paola ; Ameigeiras, Beatriz ; Preciado, María Victoria ; Valva, Pamela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5141-ec4fc14bc40b372143ee883d9d232cfed05e7621415a44e601a72a7f6d7bb2bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Biological markers</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>CD163 antigen</topic><topic>Cell activation</topic><topic>Damage assessment</topic><topic>Diagnosis</topic><topic>Disease prevention</topic><topic>Fibrosis</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>HIV</topic><topic>HIV patients</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Macrophages</topic><topic>Medicine and health sciences</topic><topic>Metabolism</topic><topic>Modelling</topic><topic>Obesity</topic><topic>Patients</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Regression models</topic><topic>Serology</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cairoli, Victoria</creatorcontrib><creatorcontrib>De Matteo, Elena</creatorcontrib><creatorcontrib>Casciato, Paola</creatorcontrib><creatorcontrib>Ameigeiras, Beatriz</creatorcontrib><creatorcontrib>Preciado, María Victoria</creatorcontrib><creatorcontrib>Valva, Pamela</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cairoli, Victoria</au><au>De Matteo, Elena</au><au>Casciato, Paola</au><au>Ameigeiras, Beatriz</au><au>Preciado, María Victoria</au><au>Valva, Pamela</au><au>Sitia, Giovanni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects</atitle><jtitle>PloS one</jtitle><date>2022-07-07</date><risdate>2022</risdate><volume>17</volume><issue>7</issue><spage>e0270911</spage><epage>e0270911</epage><pages>e0270911-e0270911</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage was evaluated in plasma samples at time of biopsy in 120 patients with different hepatic conditions (56 HCV, 20 HCV/HIV, 10 HBV and 34 MAFLD). sCD163 values were compared with those of healthy donors and analyzed related to histological damage. sCD163 together with other clinical parameters were used to create a logistical regression model to predict significant fibrosis. Only patients with viral hepatitis showed higher sCD163 values compared to the control group (HCV p<0.0001; HCV/HIV p<0.0001; HBV p = 0.0003), but no significant differences regarding fibrosis stages were observed. The proposed model predicts fibrosis severity using the logarithm sCD163 concentration, platelet count and age, it demonstrated to be a good marker for the HCV monoinfected group (AUROC 0.834) and an excellent one for the HCV/HIV co-infected group (AUROC 0.997). Moreover, the model displayed a diagnostic performance similar to FIB-4 in HCV cases and FIB-4 and APRI in HCV/HIV coinfected cases, and it even managed to correctly classify some cases that had been misclassified. The proposed model is able to determine, in a non-invasive way, the liver fibrosis stage of HCV and HCV/HIV patients, so after validation, it could be used in a complementary way in the clinical practice whenever APRI and FIB-4 failed to determine damage severity in HCV and HCV/HIV cases.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>35797388</pmid><doi>10.1371/journal.pone.0270911</doi><tpages>e0270911</tpages><orcidid>https://orcid.org/0000-0003-3994-2401</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-07, Vol.17 (7), p.e0270911-e0270911 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2686270154 |
| source | Open Access: PubMed Central; PLoS; DOAJ Directory of Open Access Journals; Free Full-Text Journals in Chemistry; EZB Electronic Journals Library |
| subjects | Analysis Biological markers Biology and Life Sciences Biomarkers Biopsy CD163 antigen Cell activation Damage assessment Diagnosis Disease prevention Fibrosis Genetic aspects Health aspects Hepatitis Hepatitis B Hepatitis C HIV HIV patients Hospitals Human immunodeficiency virus Infections Inflammation Liver Liver diseases Macrophages Medicine and health sciences Metabolism Modelling Obesity Patients Plasma Proteins Regression models Serology Variables |
| title | The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A05%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20performance%20of%20soluble%20CD163%20as%20a%20non-invasive%20biomarker%20of%20liver%20damage%20in%20chronically%20HCV%20and%20HCV/HIV%20infected%20subjects&rft.jtitle=PloS%20one&rft.au=Cairoli,%20Victoria&rft.date=2022-07-07&rft.volume=17&rft.issue=7&rft.spage=e0270911&rft.epage=e0270911&rft.pages=e0270911-e0270911&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0270911&rft_dat=%3Cgale_plos_%3EA709492350%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2686270154&rft_id=info:pmid/35797388&rft_galeid=A709492350&rft_doaj_id=oai_doaj_org_article_98dfe1108a5e447d99b13748fdc3932e&rfr_iscdi=true |